Mr. Jake opined several FUD statements. Chief among them
Mr. Jake opined several FUD statements. Chief among them was : "By my reckoning, all of this looks very doable (and with a share price surging well beyond 50 cents and perhaps as high as 1.30) by no later than 2031 or 32." Good example of soft bashing. Wow, Mr. Jake, we only look stupid. What is your motive in attempting to discourage retail investment in a drug that is going to extend a significant number of lives? Referring to an un-named poster espousing old FDA protocols is not going to impress or dissuade anybody here. I am not impressed with our current Federal landscape but the FDA is a different animal now and it will be considered a big political win for the FDA and their bosses to approve a drug that changes cancers' course sooner than later.
Currently practicing Oncologists utilize the blood concentrations of ctDNA, CAMLs, PD-L1 and other proteins to determine treatment adequacy and prognosis. These are the things that Big Pharma will come to understand that leronlimab is for real. When will they pull the trigger on a CYDY acquisition, depends on on the blood results and early CT/MRI results. No guess here on when the trigger will be pulled, but that sure isn't going to be 6 years from now.
Do you really think Dr. J. would delay the progress of leronlimab by 12-18 months waiting for 'final OS data? That would be a fatal error for a lot of people with cancer and Dr. J. understands that. Dr. J. will use all the medical and political means he has available to obtain early approval for leronlimab.
Mr. Jake, in my opinion, I don't believe that your well written post was altruistic. You did note good data in certain areas assisted by AI, but all soft bashing does similar actions. Keeping CYDY's stock price low enhances only the shorts and Big Pharma's bargaining positions.
6
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A five-hour lab result can matter more than another glossy precision-medicine slogan. MedStar Health says it is using same-day genetic testing for patients with ischemic stroke, giving clinicians information before discharge that previously often arrived more than a week later. That is a practical change, not science-fiction wallpaper: a treatment decision gets made while...
Continue Reading
Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...
Continue Reading
Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...
Continue Reading
A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...
Continue Reading
Permitting news rarely rings a cash register, but it can stop one from being bolted shut. Century Lithium has received confirmation from the Bureau of Land Management’s Tonopah Field Office that baseline studies for its wholly owned Angel Island lithium project in Esmeralda County, Nevada, are complete. The agency also set the project on the Environmental Impact...
Continue Reading
Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...
Continue Reading
Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....
Continue Reading
A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...
Continue Reading
A High Score Is Useful, Not a Free Pass Debt relief rankings can get awfully shiny when a company has a good week, but this one has some actual detail behind it. USA Today named Accredited Debt Relief its best provider for personalized debt relief in its 2026 review, handing the company a 94 out of 100. The ranking was published November 11 and updated November 12, and...
Continue Reading
Three Distillers, One Very Large Question Whisky does not become world-class because a camera crew found a pretty shoreline. That is the blunt truth sitting underneath this Nov. 19, 2026 documentary release from CCTV+. The film follows three international distillers working at three separate whisky distilleries along Qiandaohu, while also lingering on their day-to-day...
Continue Reading
Top 5 Most Recently Viewed Articles
Leadership Expansion at A&K Robotics A&K Robotics, a frontrunner in the autonomous micromobility sector, is excited to welcome Melonee Wise to its Board of Advisors. With over twenty years of rich experience in developing robotic technologies, Wise is poised to offer invaluable insights as the company continues to grow its influence worldwide. Advancing Mobility Through...
Continue Reading
Lavior Welcomes Ryan Shilling as New VP of Sales for U.S. Healthcare Expertise to Drive Growth and Patient-Centered Innovation Lavior, an innovator in advanced healing solutions, proudly announces the appointment of Ryan Shilling as Vice President of Sales for the U.S. market. With over 15 years of leadership experience in various healthcare sectors, Shilling is set to...
Continue Reading
Tesla Gears Up for Cybertruck Deliveries in Canada Tesla Inc. (NASDAQ: TSLA) is approaching an exciting milestone as it plans to start delivering its much-anticipated Cybertruck in Canada shortly. Recent updates on social media suggest that the event could happen as early as next week, thrilling prospective owners. Exciting Customer Announcements On social media platform...
Continue Reading
Borregaard ASA Ex-Dividend Trading Insights Today marks the beginning of a new trading phase for Borregaard ASA as its shares are now officially traded ex-dividend at NOK 4.25 per share. This means that investors purchasing shares at this point will not receive the forthcoming dividend, which can influence buying decisions in the market. Understanding Ex-Dividend Dates...
Continue Reading
Current Updates on Charter Communications, Inc. Charter Communications, Inc. (NASDAQ: CHTR) has been generating significant attention as it faces an ongoing class action lawsuit regarding securities fraud. This legal proceeding serves to remind shareholders of their rights and the timelines that are critical for participation. With the stakes involved, it is vital for...
Continue Reading